Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

GIND scientists identify drug treatments that can normalize neuron development in AD

Scientists at the Gladstone Institute of Neurological Disease (GIND) have discovered that two main causes of AD amyloid-beta (Aβ) peptides and apolipoprotein E4 (apoE4) impair the growth of new neurons born in adult brains. What is more, they have identified drug treatments that can normalize the development of these cells even in the presence of Aβ or apoE4. The findings are described in two separate papers published in the current issue of Cell Stem Cell.

4 Dec 2009

TapeBeat.Com posts research on GeneLink

TapeBeat.Com the news and community portal for the serious investor has posted research on GeneLink (GNLK). GeneLink’s approach to well-being utilizes the science of pharmacogenenomics - using individual genetic variations to customize nutritional, skincare products and health maintenance products.

4 Dec 2009

Shorter amyloid fibres more toxic than longer counterparts, says study

A major discovery is challenging accepted thinking about amyloids - the fibrous protein deposits associated with diseases such as Alzheimer's and Parkinson's - and may open up a potential new area for therapeutics.

4 Dec 2009

New research trial to study the impact of exercise on Parkinson's patients

Officials at the new Muhammad Ali Parkinson Center at Barrow Neurological Institute announced today the center's participation in a novel Parkinson's study aimed at determining the physical and neurological impact of simple exercise on Parkinson's patients.

4 Dec 2009

Combination of green tea and DAPH-12 chemicals may help prevent brain disorders

Scientists at Boston Biomedical Research Institute (BBRI) and the University of Pennsylvania have found that combining two chemicals, one of which is the green tea component EGCG, can prevent and destroy a variety of protein structures known as amyloids. Amyloids are the primary culprits in fatal brain disorders such as Alzheimer's, Huntington's, and Parkinson's diseases.

4 Dec 2009

New biochemical probe may help in identifying toxic proteins associated with Alzheimer's disease

Alzheimer's disease (AD) is one of the most heartbreaking diagnoses a person can receive. This irreversible, progressive brain disease slowly destroys memory and thinking skills and eventually even the ability to carry out the simplest tasks

4 Dec 2009

Study shows younger, female and Hispanic stroke survivors are less likely to take antithrombotic medications

People who have had an ischemic stroke are at higher lifetime risk for another stroke, but several types of medication can reduce that risk. One of the simplest regimens involves antithrombotic medications, otherwise known as blood thinners, of which the most common is aspirin.

3 Dec 2009

Most of the fatal falls in the home can be avoided with fall prevention and protection products

Healthcare costs are rapidly increasing due to the rapid aging of our population. The Center for Disease Control and Prevention indicates that over 60% of fatal falls occur in the home. Additionally, the total cost of falls in 2010 is expected to be between 68 and 100 Billion Dollars. More than 25,000 older adults died due to falls last year.

3 Dec 2009

Arizona SunView Care Center acquired by The Ensign Group

The Ensign Group, Inc., announced today that it has acquired SunView Care Center, an operating skilled nursing and Alzheimer's campus in Youngtown, Arizona, a sister community adjacent to Arizona's Sun City retirement community. The acquisition was effective December 1, 2009.

3 Dec 2009

Care Support of America's outpatient palliative care coordination model improves the quality of life for seniors

Care Support of America's model of outpatient palliative care coordination, Advanced Illness Coordinated Care (AICC), has been shown to reduce hospitalizations in the last years of life as well as improve the quality of life for seniors and their family caregivers without increasing mortality. These are the principal findings of a new study published in American Journal of Managed Care (November 2009).

3 Dec 2009

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

AstraZeneca and Targacept, Inc. today announced a collaboration and license agreement for the global development and commercialization of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD).

3 Dec 2009

AclarusDx Alzheimer’s test now available as RUO product

ExonHit Therapeutics is pleased to announce that AclarusDx™ Alzheimer’s test (formerly known as EHT Dx21), its blood-based test for the detection of Alzheimer’s disease (AD), is now available as a Research Use Only (RUO) product for pharmaceutical companies and leading academic centers conducting clinical trials in Alzheimer’s disease.

3 Dec 2009

Dementia patients with certain changes in their brain's white matter more likely to be apathetic

Dementia patients with a certain type of changes in their brain's white matter are more likely to be apathetic than those who do not have these changes, reveals a patient study carried out by the Sahlgrenska Academy and Sahlgrenska University Hospital.

3 Dec 2009

Research study compares genetic make-up of humans and primates

In spite of their genetic similarity to humans, chimpanzees and great apes have maximum lifespans that rarely exceed 50 years. The difference, explains USC Davis School of Gerontology Professor Caleb Finch, is that as humans evolved genes that enabled them to better adjust to levels of infection and inflammation and to the high cholesterol levels of their meat rich diets.

3 Dec 2009

FDA approves revised clinical trial protocol for CytRx' arimoclomol

CytRx Corporation, a biopharmaceutical company, is permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate arimoclomol as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), following the U.S. Food and Drug Administration’s (FDA) acceptance of a revised clinical trial protocol.

2 Dec 2009

Accera Pharmaceuticals to implement the Veeva CRM suite of multi-tenant SaaS applications

Less than 9 months after implementing a new CRM application, Accera Pharmaceuticals began searching for a replacement. The commercial-stage biotechnology company, which launched Axona™ (a prescription-only medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease) around the same time as it implemented its current system, had quickly outgrown the generic CRM tool.

2 Dec 2009

A leader in the fight against brain diseases and in drug discovery joins UF

A leader in the fight against brain diseases and in drug discovery to help Alzheimer's patients has joined the University of Florida College of Medicine, interim dean Michael Good, M.D., announced.

2 Dec 2009

DiaMedica to acquire all issued and outstanding shares of Sanomune

DiaMedica Inc. (TSX VENTURE:DMA)("Diamedica"), a biopharmaceutical company that has discovered and is developing a novel approach to treating diabetes, announces it has entered into a non-binding letter of intent to acquire all of the issued and outstanding shares of Sanomune Inc.

2 Dec 2009

MRI pioneer honored with MRC Millennium Medal

Sir Peter Mansfield, The University of Nottingham's Nobel Laureate for Physiology and Medicine, is to be recognised, once again, for his part in one of the most important breakthroughs in medical science.

2 Dec 2009

Glutamatergic nerve cells regularly generated in the brain

Until only a few years ago, neurogenesis - the process of nerve cell development - was considered to be impossible in the adult brain. The textbooks asserted that dead nerve cells could not be replaced. Then researchers discovered regions in the forebrain in humans in which new nerve cells can be generated throughout life. These so-called GABAergic cells use gamma-aminobutyric acid (GABA), a neurotransmitter of the central nervous system.

1 Dec 2009

Alzheimer's Disease News and Research

Further Reading

GIND scientists identify drug treatments that can normalize neuron development in AD

TapeBeat.Com posts research on GeneLink

Shorter amyloid fibres more toxic than longer counterparts, says study

New research trial to study the impact of exercise on Parkinson's patients

Combination of green tea and DAPH-12 chemicals may help prevent brain disorders

New biochemical probe may help in identifying toxic proteins associated with Alzheimer's disease

Study shows younger, female and Hispanic stroke survivors are less likely to take antithrombotic medications

Most of the fatal falls in the home can be avoided with fall prevention and protection products

Arizona SunView Care Center acquired by The Ensign Group

Care Support of America's outpatient palliative care coordination model improves the quality of life for seniors

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

AclarusDx Alzheimer’s test now available as RUO product

Dementia patients with certain changes in their brain's white matter more likely to be apathetic

Research study compares genetic make-up of humans and primates

FDA approves revised clinical trial protocol for CytRx' arimoclomol

Accera Pharmaceuticals to implement the Veeva CRM suite of multi-tenant SaaS applications

A leader in the fight against brain diseases and in drug discovery joins UF

DiaMedica to acquire all issued and outstanding shares of Sanomune

MRI pioneer honored with MRC Millennium Medal

Glutamatergic nerve cells regularly generated in the brain

Aneuro: A Year of Neuroscience in Review eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News